Opinion/decision on a Paediatric investigation plan (PIP): Beyfortus, Nirsevimab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vaccines, PIP number: P/0296/2021

Opinion/decision on a Paediatric investigation plan (PIP): Kisplyx, Lenvatinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0528/2022

Opinion/decision on a Paediatric investigation plan (PIP): Taltz, ixekizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0087/2020

Opinion/decision on a Paediatric investigation plan (PIP): Blincyto, blinatumomab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0449/2023

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0527/2021

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0172/2021

Opinion/decision on a Paediatric investigation plan (PIP): Translarna, Ataluren, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0196/2023

Opinion/decision on a Paediatric investigation plan (PIP): Zavicefta, Ceftazidime,Avibactam, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0551/2022

EMEA-001662-PIP01-14-M05

Opinion/decision on a Paediatric investigation plan (PIP): Otezla, apremilast, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0469/2020